Selection of a novel cell-internalizing RNA aptamer specific for CD22 antigen in B cell acute lymphoblastic leukemia

Dario Ruiz-Ciancio; Li-Hsien Lin; Suresh Veeramani; Maya N. Barros; Diego Sanchez; Ary Lautaro Di Bartolo; Diego Masone; Paloma H. Giangrande; María Belén Mestre; William H. Thiel

doi:10.1016/j.omtn.2023.07.028

Back

Selection of a novel cell-internalizing RNA aptamer specific for CD22 antigen in B cell acute lymphoblastic leukemia

Journal article

Open access

Peer reviewed

Selection of a novel cell-internalizing RNA aptamer specific for CD22 antigen in B cell acute lymphoblastic leukemia

Dario Ruiz-Ciancio, Li-Hsien Lin, Suresh Veeramani, Maya N. Barros, Diego Sanchez, Ary Lautaro Di Bartolo, Diego Masone, Paloma H. Giangrande, María Belén Mestre and William H. Thiel

Molecular therapy. Nucleic acids, Vol.33, pp.698-712

09/01/2023

DOI: 10.1016/j.omtn.2023.07.028

PMCID: PMC10469072

PMID: 37662970

Files and links (1)

url

https://doi.org/10.1016/j.omtn.2023.07.028View

Published (Version of record) Open Access

Abstract

Despite improvements in B cell acute lymphoblastic leukemia (B-ALL) treatment, a significant number of patients experience relapse of the disease, resulting in poor prognosis and high mortality. One of the drawbacks of current B-ALL treatments is the high toxicity associated with the non-specificity of chemotherapeutic drugs. Targeted therapy is an appealing strategy to treat B-ALL to mitigate these toxic off-target effects. One such target is the B cell surface protein CD22. The restricted expression of CD22 on the B-cell lineage and its ligand-induced internalizing properties make it an attractive target in cases of B cell malignancies. To target B-ALL and the CD22 protein, we performed cell internalization SELEX (Systematic Evolution of Ligands by EXponential enrichment) followed by molecular docking to identify internalizing aptamers specific for B-ALL cells that bind the CD22 cell-surface receptor. We identified two RNA aptamers, B-ALL1 and B-ALL2, that target human malignant B cells, with B-ALL1 the first documented RNA aptamer interacting with the CD22 antigen. These B-ALL-specific aptamers represent an important first step toward developing novel targeted therapies for B cell malignancy treatments.

aptamer

B cell acute lymphoblastic leukemia

CD22 protein

cell internalization SELEX

molecular docking

MT: Delivery Strategies

Details

Title: Subtitle: Selection of a novel cell-internalizing RNA aptamer specific for CD22 antigen in B cell acute lymphoblastic leukemia
Creators: Dario Ruiz-Ciancio
Li-Hsien Lin - University of Iowa
Suresh Veeramani
Maya N. Barros - Department of Internal Medicine, University of Iowa, Iowa City, IA 52246, USA
Diego Sanchez - Instituto de Medicina y Biología Experimental de Cuyo
Ary Lautaro Di Bartolo - Instituto de Histología y Embriología de Mendoza
Diego Masone - Instituto de Histología y Embriología de Mendoza
Paloma H. Giangrande
María Belén Mestre
William H. Thiel
Resource Type: Journal article
Publication Details: Molecular therapy. Nucleic acids, Vol.33, pp.698-712
DOI: 10.1016/j.omtn.2023.07.028
PMID: 37662970
PMCID: PMC10469072
NLM abbreviation: Mol Ther Nucleic Acids
ISSN: 2162-2531
eISSN: 2162-2531
Publisher: Elsevier
Language: English
Date published: 09/01/2023
Academic Unit: Hematology, Oncology, and Blood & Marrow Transplantation; Cardiovascular Medicine; Internal Medicine
Record Identifier: 9984455982102771

Metrics

16 Record Views

5 Times Cited - Web of Science

See more details